Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Medtronic PLC    MDT   IE00BTN1Y115

MEDTRONIC PLC

(MDT)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Medtronic : Announces Cash Dividend for Third Quarter of Fiscal Year 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 06:46am EST

Medtronic plc

DUBLIN - December 7, 2018 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 third quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2018. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 41 consecutive years. The dividend is payable on January 18, 2019, to shareholders of record at the close of business on December 28, 2018.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Fernando Vivanco
Public Relations
+1-763-505-3780

Ryan Weispfenning
Investor Relations
+1-763-505-4626





This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC PLC
02/20MEDTRONIC : EVP & RTG President Geoff Martha to Speak at Leerink Partners Global..
AQ
02/20MEDTRONIC : Announces U.S. Commercial Launch of Deep Brain Stimulation for Medic..
AQ
02/20MEDTRONIC PLC : Regulation FD Disclosure, Other Events (form 8-K)
AQ
02/20MEDTRONIC : Announces Cash Tender Offer for Certain Outstanding Debt Securities ..
AQ
02/20MEDTRONIC : Medical Devices Bolster Medtronic
DJ
02/19MARKET SNAPSHOT: Stocks Close Higher As Defensive Sectors Lead; Nasdaq Gains ..
DJ
02/19MEDTRONIC : Swings to Profit Despite Slowdown in Heart-Failure Treatments -- Upd..
DJ
02/19Medtronic quarterly profit beats on strength in surgical products
RE
02/19MEDTRONIC : Q3 FY19 Earnings Commentary
PU
02/19GLOBAL MARKETS LIVE : Walmart, Honda, Tom Tailor, Facebook…
More news
Financials ($)
Sales 2019 30 543 M
EBIT 2019 8 816 M
Net income 2019 4 986 M
Debt 2019 17 964 M
Yield 2019 2,12%
P/E ratio 2019 25,62
P/E ratio 2020 22,96
EV / Sales 2019 4,70x
EV / Sales 2020 4,46x
Capitalization 126 B
Chart MEDTRONIC PLC
Duration : Period :
Medtronic PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 103 $
Spread / Average Target 9,8%
EPS Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Mark Ploof Senior Vice President-Global Operations
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC3.09%125 707
BAXTER INTERNATIONAL12.47%39 740
ZIMMER BIOMET HOLDINGS19.98%25 383
HOYA CORPORATION4.82%23 322
TERUMO CORP9.74%22 876
ALIGN TECHNOLOGY21.74%20 315